ନିର୍ମାଟ୍ରେଲଭିର/ରିଟୋନାଭିର

ନିର୍ମାଟ୍ରେଲଭିର/ରିଟୋନାଭିର
	Package of a days worth of Paxlovid in those with normal kidney function.
Combination of
Nirmatrelvir	Antiviral drug
Ritonavir	CYP3A inhibitor
Clinical data
Trade names	Paxlovid
Synonyms	Nirmatrelvir/r
data	US DailyMed: Nirmatrelvir;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only via emergency use authorization;

ଯା

ନିର୍ମାଟ୍ରେଲଭିର/ରିଟୋନାଭିର ଔଷଧ ଦ୍ୱୟ ଏକତ୍ର ପ୍ୟାକେଜ ଆକାରରେ ବିକ୍ରୟ ହେଉଛି ଯାହାର ନାମ ପ୍ୟାକ୍ସଲୋଭିଡ ଏବଂ ଏହା କୋଭିଡ-୧୯ର (COVID-19) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୧] ଲକ୍ଷଣ ଆରମ୍ଭ ହେବାର ୫ ଦିନ ମଧ୍ୟରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେଉଁମାନଙ୍କ ପାଇଁ ଅମ୍ଳଜାନ ଆବଶ୍ୟକ ହୁଏ ନାହିଁ, କିନ୍ତୁ ଗୁରୁତର କୋଭିଡ-୧୯ ରୋଗ ହେବାର ଆଶଙ୍କା ଅଧିକ ଥାଏ ।^[୧] ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱାଦ ସମସ୍ୟା, ତରଳ ଝାଡ଼ା, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ । ^[୩] ଗର୍ଭାବସ୍ଥାରେ ଏହି ଔଷଧ ଦେଲେ ତାହାର ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୧] ଯକୃତ କିମ୍ବା ବୃକ୍‌କ ଜନିତ ସମସ୍ୟା ଥିବା ଲୋକଙ୍କଠାରେ ଏହା ବ୍ୟବହାର କରାଯିବା ଉଚିତ୍ ନୁହେଁ । ^[୧] ଏଥିରେ ଅନେକ ଔଷଧମାନଙ୍କ ସ‌ହିତ ହରମୋନାଲ ଜନ୍ମ ନିୟନ୍ତ୍ରଣ ଔଷଧର ମଧ୍ୟ ପ୍ରତିକ୍ରିୟା ହେବା ସମ୍ଭାବନା ରହିଛି ।^[୩] ^[୧] ଏଥିରେ ଥିବା ନିର୍ମାଟ୍ରେଲଭିର ଏକ୨୦୧୯ ନୂତନ କରୋନା ଭୂତାଣୁର ପ୍ରୋଟିଏଜ ଇନହିବିଟର ଏବଂ ରିଟୋନାଭିର ଥାଏ ଯେଉଁଥିରେ ଏକ ସିୱାଇପି୩ଏ (CYP3A) ନିରୋଧକ ଥାଏ।| ^[୩]

ଯୁକ୍ତରାଜ୍ୟରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଡିସେମ୍ବର ୨୦୨୧ରେ ଏହି ମିଶ୍ରଣକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା । ^[୧] ସେହି ମାସରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ନିମନ୍ତେ ମଧ୍ୟ ଅନୁମତି ପାଇଥିଲା ।^[୩] ୨୦୨୧ ମସିହାରେ ଆମେରିକା ସରକାର ଆମେରିକୀୟମାନଙ୍କୁ ବିନା ମୂଲ୍ୟରେ ପ୍ରଦାନ କରିବା ପାଇଁ ପ୍ରତ୍ୟେକ କୋର୍ଷର ଚିକିତ୍ସା ନିମନ୍ତେ ୫୩୦ ଡଲାର ହିସାବରେ ୧୦ ନିୟୁତ ଚିକିତ୍ସା କୋର୍ଷ ବା ଧାରା କିଣିଥିଲେ ।^[୬] ^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Summary of Product Characteristics for Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
↑ "Regulatory approval of Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 11 January 2022. Retrieved 31 December 2021.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Paxlovid- nirmatrelvir and ritonavir kit". DailyMed. Archived from the original on 31 December 2021. Retrieved 30 December 2021.
↑ "FDA Authorizes First Oral Antiviral for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 22 December 2021. Archived from the original on 27 December 2021. Retrieved 22 December 2021. This article incorporates text from this source, which is in the public domain.
↑ Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021.
↑ "U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for $5.3 bln". Reuters. 18 November 2021. Archived from the original on 3 January 2022. Retrieved 6 January 2022.
↑ "FDA Grants Pfizer's COVID Antiviral Pill EUA - GoodRx". GoodRx. Archived from the original on 31 December 2021. Retrieved 6 January 2022.

[UK2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Summary of Product Characteristics for Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.

[2] "Regulatory approval of Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 11 January 2022. Retrieved 31 December 2021.

[PI2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Paxlovid- nirmatrelvir and ritonavir kit". DailyMed. Archived from the original on 31 December 2021. Retrieved 30 December 2021.

[FDA_PR_20211222-4] "FDA Authorizes First Oral Antiviral for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 22 December 2021. Archived from the original on 27 December 2021. Retrieved 22 December 2021. This article incorporates text from this source, which is in the public domain.

[FDA2022Fact-5] Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021.

[6] "U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for $5.3 bln". Reuters. 18 November 2021. Archived from the original on 3 January 2022. Retrieved 6 January 2022.

[7] "FDA Grants Pfizer's COVID Antiviral Pill EUA - GoodRx". GoodRx. Archived from the original on 31 December 2021. Retrieved 6 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]